Storaktionærmeddelelse - Pharma Equity Group A/S
23 avr. 2024 05h45 HE
|
Pharma Equity Group A/S
Storaktionærmeddelelse - Pharma Equity Group A/S 23. april 2024Selskabsmeddelelse nr. 14 Pharma Equity Group A/S har i henhold til kapitalmarkedslovens § 38 modtaget storaktionærmeddelelse om,...
Major shareholder announcement - Pharma Equity Group A/S
23 avr. 2024 05h45 HE
|
Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S 23 April 2024Company Announcement no. 14 Pharma Equity Group A/S has, in accordance with section 38 of the Capital Markets Act, received...
Forløb af generalforsamlingen i Pharma Equity Group A/S
16 avr. 2024 11h29 HE
|
Pharma Equity Group A/S
Forløb af generalforsamlingen i Pharma Equity Group A/S 16. april 2024Selskabsmeddelelse nr. 13 Pharma Equity Group A/S har i dag afholdt ordinær generalforsamling med følgende resultat: 1)...
Passing of the General Meeting of Pharma Equity Group A/S
16 avr. 2024 11h29 HE
|
Pharma Equity Group A/S
Passing of the General Meeting of Pharma Equity Group A/S 16 April 2024Company Announcement no. 13 Pharma Equity Group A/S today held its Annual General Meeting with the following results: 1)...
Bestyrelsens beslutning om udstedelse af konvertible lån
10 avr. 2024 08h21 HE
|
Pharma Equity Group A/S
Bestyrelsens beslutning om udstedelse af konvertible lån 10. april 2024Meddelelse nr. 12 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af yderligere konvertible lån i...
The Board of Director's decision to issue convertible loans
10 avr. 2024 08h21 HE
|
Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans 10 April 2024Company Announcement no. 12 The Board of Directors of Pharma Equity Group has decided on the issuance of additional...
Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, rapporterer meget positive slutresultater fra det klinisk fase-2 studie med selskabets patenterede lægemiddelkandidat RNX-051.
05 avr. 2024 05h22 HE
|
Pharma Equity Group A/S
5. april 2024 Meddelelse nr. 11 Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, rapporterer meget positive slutresultater fra det klinisk fase-2 studie med selskabets patenterede...
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
05 avr. 2024 05h22 HE
|
Pharma Equity Group A/S
5 April 2024 Company Announcement No. 11 Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s...
Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S
25 mars 2024 08h06 HE
|
Pharma Equity Group A/S
25. marts 2024 Meddelelse nr. 10 Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S Bestyrelsen indkalder hermed til den ordinære generalforsamling i Pharma Equity Group A/S...
Notice convening the annual general meeting in Pharma Equity Group A/S
25 mars 2024 08h06 HE
|
Pharma Equity Group A/S
25 March 2024 Announcement no. 10 Notice convening the annual general meeting in Pharma Equity Group A/S The board of directors hereby convenes the annual general meeting in Pharma...